Can things go wrong years after limb lengthening surgery?

Surgeons split complications into three time windows. Intra-operative events happen during surgery, vascular injury, malposition of the implant, anesthesia-related events. They are rare and not the subject of this article. Early complications happen in the first 12 months, during distraction (weeks 1-10) and consolidation (months 3-9). Almost all the headline complication numbers in published systematic reviews (30-45% any, 5-15% serious) describe this window.

Late complications are anything past 12 months. The implant has usually been removed at 12-18 months. Bone consolidation is largely complete. The patient is back to walking unaided and most are back to running and impact sport. This is when the picture shifts. The serious complications that emerge late are a smaller, narrower set than the early ones, but they are the ones that can affect a patient for the rest of their life.

Most published series report 12-24 month outcomes. The 2025 JOSR systematic review (PMC11415641, n=1,847) noted that long-term follow-up was the weakest part of the cosmetic-LL evidence base. Anything we say about 5-year or 10-year cosmetic LL outcomes draws partly on reconstructive-LL data, where 30+ years of follow-up is available, and partly on the early cohorts of internal-nail patients who are just now reaching those time points.

Refracture of the newly-lengthened bone is the most common late complication in cosmetic LL. Published rates run 1-3% in the first 24 months across all methods, with most series pooling "late refracture" with consolidation-phase fractures because the distinction is academic. The specific pattern that matters: patients who returned to impact sport between months 6 and 12, before bone density at the regenerate had matched native bone, account for a disproportionate share of these fractures.

Internal-nail patients carry a specific risk. Once the implant is removed at 12-18 months, the bone is structurally sound but still slightly less dense than native bone at the lengthened segment for another 6-12 months. The visual absence of external hardware creates what surgeons call "false sense of recovery", the patient feels fully healed, sees no external pin marks, and assumes the surgery is behind them. The bone disagrees. Series following PRECICE patients past the 18-month mark report that refractures past 24 months are vanishingly rare, but the year-2 window is real.

The single biggest predictor of late refracture is return-to-sport timing. Surgeons at Paley Institute, HSS, and the Rubin Institute use roughly the same protocol: walking without aids at 4-6 months, jogging at 9-12 months, impact sport (running, basketball, soccer) at 12 months minimum, and contact sport at 18-24 months. Patients who compress this timeline by 3-6 months account for most published refractures. Patients who follow it land in the 99%+ refracture-free cohort.

Treatment of late refracture is repeat immobilisation, sometimes a second internal nail, and another 3-6 months out of activity. It is recoverable but not painless.

Nerve injury during distraction is a documented complication of cosmetic LL, with the JOSR 2025 review reporting 3.2% nerve compression pooled across methods. Most nerve events (~80%) are transient and resolve within 3-9 months. The remaining 20% are not, and that is the late-complication population.

The classic pattern is peroneal nerve injury during tibial lengthening. The peroneal nerve sits in a tight osseofascial tunnel below the knee, and tibial distraction stretches it more than the surrounding tissue can accommodate in some patients. Symptoms range from persistent foot drop (visible weakness in lifting the foot) to sensory loss along the outside of the lower leg or top of the foot, to chronic neuropathic pain that may not respond to standard analgesia.

Long-term incidence of permanent nerve injury after cosmetic LL runs 2-8% across published series, depending on whether tibial or femoral lengthening is the dominant case mix in the series. Femoral lengthening carries lower nerve risk than tibial lengthening, the femur is shorter, the sciatic nerve runs more laterally, and the stretch tolerance is higher. Patients undergoing tibial-only lengthening should ask their surgeon directly about the published series' tibial-specific nerve injury rate, not the all-segment pooled rate.

Management is multidisciplinary. Mild persistent symptoms are managed with neuropathic-pain medications (gabapentin, pregabalin) and physiotherapy. More severe cases may need ankle-foot orthoses for foot drop, or surgical decompression if a specific compression point can be identified on EMG. Outcomes at 5 years are highly individual: roughly half of patients with persistent symptoms at 12 months see further improvement through year 3; the rest stabilise at whatever functional level they reach by month 18.

Range-of-motion loss at the joints above and below the lengthened bone is the third major late complication and the one most directly caused by patient behaviour during recovery. Approximately 10-15% of patients show measurable ROM loss at 2 years post-op, typically reduced knee flexion (after femur lengthening) or reduced ankle dorsiflexion (after tibia lengthening). Most are small enough not to affect daily function, but a subset are not.

The mechanism is straightforward. Distraction stretches the musculotendinous units that cross the lengthened bone. Calf muscles, hamstrings, and the iliotibial band lengthen alongside the bone, but they require active and passive physiotherapy throughout distraction and consolidation to maintain their normal excursion. Patients who skip physiotherapy, who reduce it from twice-daily to weekly, or who stop entirely once the active distraction phase ends, will lose ROM at the adjacent joints.

ROM loss past month 12 is harder to recover than ROM loss at month 4. The tissue has had time to remodel in the contracted position. Recovering 10 degrees of knee flexion at month 18 may take 3-6 months of dedicated physiotherapy; recovering it at month 4 takes 4-6 weeks. The earliest patient instinct to deprioritise physiotherapy ("the bone is the surgery, this stretching is optional") is the single most consequential mistake a recovering patient can make.

Many clinics now bundle 4-8 weeks of in-house physiotherapy with the surgical package; some Turkish centers (LiveLifeTaller, Wanna Be Taller, Acibadem) include 12+ weeks for international patients. Whatever is bundled is a floor, not a ceiling, most patients need 9-12 months of physiotherapy total to reach full functional recovery.

Implant-related late complications are dominated by one device-specific case: the Stryde recall. The PRECICE Stryde nail received an FDA Class I recall in April 2021 after reports of corrosion at the telescoping junction and adjacent bone changes (focal osteolysis). Existing Stryde patients carry an ongoing implant-monitoring obligation that other internal-nail patients do not, imaging every 6-12 months for at least 3 years post-op, with elective removal recommended at the end of consolidation. We covered the Stryde story in detail in a dedicated article.

For PRECICE 2 and PRECICE Max patients, the current implant standard, late implant-related events are rare. The platforms have not shown the corrosion signature that Stryde did, and the titanium construction does not provoke the immune response that the Stryde stainless-steel-junction did. The implant is removed at 12-18 months in cosmetic indication, which means any patient past that timeline no longer has an implant to worry about. Reconstructive patients sometimes retain implants longer if removal carries surgical risk; for those patients the 5-10 year imaging surveillance is standard.

External-fixator patients (Ilizarov, LON during the fixator phase) have no late implant-related events because the fixator is removed at the end of the distraction phase. Pin-site scarring is permanent but not a complication in the medical sense. Pin-tract bone defects can persist for 6-12 months but heal completely in almost all patients.

Beyond the medical complications, a smaller but real category of late events involves body proportions and cosmetic outcome. Most cosmetic LL patients gain 6-8 cm in the femur or 5-7 cm in the tibia. Patients who push to the upper end of that range, or who do both femur and tibia in two stages, can reach 7-8 inches of total height gain. At those levels, torso-to-leg ratio changes, the limbs are longer relative to the upper body than they were pre-surgery, and a small share of patients report visible disproportion that they did not anticipate.

The literature treats this as a satisfaction outcome rather than a complication. The 2025 JOSR review reported overall satisfaction rates of 88-98% across cosmetic series, but those rates aggregate everyone who underwent the surgery. The 2-12% dissatisfaction band is heterogeneous: some are patients who experienced a medical complication; some are patients whose proportion concerns developed at 12-24 months when they could see the final cosmetic result; some are patients whose expectations did not align with surgical reality from the start.

The specific risk profile is well documented. Patients with pre-existing body image concerns, patients pursuing larger-than-recommended gains, and patients who under-rotated their physiotherapy commitment are over-represented in the dissatisfaction cohort. The 2018 Plastic and Reconstructive Surgery psychology literature on cosmetic-stature patients identified body dysmorphic disorder as a contraindication for cosmetic LL, preoperative psychological evaluation is now standard practice at most Tier 1 centers in 2026, and a small number of patients are screened out at this stage.

The operational point is that cosmetic regret is reduced by realistic preoperative counselling rather than by the surgical technique. A patient who clearly understands the proportional change before booking is unlikely to be surprised by it 24 months later. A patient who pursued cosmetic LL to fix something other than height, a relationship problem, a career insecurity, a deeper body image concern, may experience the cosmetic outcome as a disappointment regardless of the surgical result.

This is the part of the cosmetic-LL evidence base where honest disclosure is required. Reconstructive limb lengthening has 30+ years of follow-up. The technique itself (Ilizarov, then later internal nails) was developed in the 1950s-1970s for limb-length discrepancy, dwarfism, and post-trauma reconstruction. Five-year and ten-year outcomes are well characterised in that population.

Pure cosmetic limb lengthening with internal magnetic nails is much younger. PRECICE 1 launched in 2011. PRECICE 2 around 2015. Stryde launched in 2018 and was withdrawn in 2021. PRECICE Max first US implants were late 2023. The cohort of cosmetic-indication PRECICE patients with 10+ years of follow-up is small, and most of those patients were operated on by the same handful of surgeons (Paley, Rozbruch, Iobst, Mahboubian) at high-volume centers. We do not have large-cohort 10-year cosmetic-LL data in the way we have it for total hip replacement.

What we do have suggests two things. The anatomical principle is that the lengthened bone, once consolidated, behaves like native bone. Histological studies of the regenerate at 5+ years post-op show normal cortical and trabecular architecture. The mechanical principle is consistent: late refractures past year 5 are vanishingly rare in any series with that follow-up duration. The remaining concerns at 5-10 years are joint-mediated, knee and ankle osteoarthritis in the lengthened segment, and patients who lengthened beyond 8 cm per segment carry a slightly higher osteoarthritis signal in middle age, per reconstructive-cohort data.

This is the honest answer: the surgery itself appears durable past year 5, but our confidence at year 10+ for the cosmetic indication is constrained by cohort age. Patients undergoing cosmetic LL in 2026 are signing up to be part of the long-term surveillance population. That is not a reason not to do the surgery; it is a reason to choose a surgeon and center that participates in long-term follow-up registries and to commit, in advance, to that follow-up regardless of how recovered the patient feels at year 2.

Most late complications are scheduled into the recovery the day a patient decides to skip physiotherapy or to return to running at month 8 instead of month 12. The prevention framework is unglamorous and concrete.

Follow the physiotherapy protocol the surgeon prescribes, for the duration prescribed. Most patients need 9-12 months total. Twice-daily during distraction (weeks 1-10), daily during consolidation (months 3-9), 3-4 times weekly through month 12. Patients who reduce this on their own initiative account for most late ROM loss.

Follow the return-to-sport timeline exactly. Walking unaided at 4-6 months. Jogging at 9-12 months. Impact sport (running, basketball, tennis) at 12 months minimum. Contact sport at 18-24 months. Patients who shortcut this account for most late refractures.

Attend follow-up imaging on schedule. Most cosmetic LL surgeons schedule imaging at months 3, 6, 12, 18, and 24, then annually through year 5. Patients who skip the year-2 or year-3 visit because they feel fine miss the imaging surveillance that catches asymptomatic problems early.

Maintain contact with your surgeon for at least 5 years post-op. International patients should establish a local orthopedic surgeon in their home city before they fly home, a clinic that has not arranged this for you has not thought about your post-op care.

Report new symptoms immediately. Calf pain at month 14 is not normal. Knee stiffness at month 18 is not normal. Foot tingling at month 24 is not normal. Patients who wait 6 months hoping symptoms will resolve give the underlying problem time to become harder to fix.